Shingles Vaccine Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research presents an exhaustive analysis of the global Shingles Vaccine Market, providing detailed insights into market dynamics, key growth drivers, challenges, and emerging trends. This report serves as a comprehensive guide for stakeholders, offering in-depth data and statistics for navigating the market landscape from 2024 to 2031.

The global shingles vaccine market is anticipated to witness robust growth during the forecast period, with an estimated CAGR of 13.9%. The market is expected to expand from USD 5.1 billion in 2024 to USD 12.7 billion by 2031.

Key Insights:

Estimated Market Value (2024): USD 5.1 Billion
Projected Market Value (2031): USD 12.7 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 13.9%

Shingles Vaccine Market - Report Scope:

Shingles, caused by the reactivation of the varicella-zoster virus, predominantly affects older adults and individuals with weakened immune systems. The introduction of shingles vaccines has significantly reduced the burden of this disease, leading to widespread adoption globally.

The market for shingles vaccines is primarily driven by increasing awareness about vaccination, particularly among the elderly population. Governments and healthcare organizations worldwide are actively promoting vaccination campaigns to prevent shingles-related complications, such as postherpetic neuralgia.

Market Growth Drivers:

Several factors contribute to the growth of the shingles vaccine market. The aging population, coupled with a higher risk of shingles among older adults, drives vaccine demand. Additionally, advancements in vaccine technology have led to the development of more efficacious and longer-lasting vaccines, further boosting market growth.

Moreover, the growing emphasis on preventive healthcare, particularly in developed regions, encourages vaccination against shingles. Healthcare professionals play a crucial role in recommending and administering vaccines, contributing to increased vaccine uptake.

Market Restraints:

Despite its positive growth trajectory, the shingles vaccine market faces certain challenges. Limited access to healthcare services in rural and underserved areas restricts vaccine distribution, particularly in developing regions. Furthermore, vaccine hesitancy and misconceptions about vaccine safety and efficacy hinder uptake rates, impacting market growth.

The high cost of shingles vaccines, especially in regions without universal healthcare coverage, poses a barrier to access for some individuals. Additionally, the availability of generic antiviral medications for shingles treatment may deter some patients from opting for vaccination, especially if they perceive vaccines as less cost-effective.

Market Opportunities:

The shingles vaccine market presents several opportunities for expansion and innovation. Efforts to improve vaccine accessibility through government-sponsored immunization programs and community outreach initiatives can enhance vaccine uptake rates, particularly among underserved populations.

Furthermore, ongoing research and development activities aimed at developing next-generation shingles vaccines, including adjuvanted and recombinant vaccines, hold promise for improved efficacy and durability. Expansion into emerging markets with growing elderly populations presents untapped opportunities for vaccine manufacturers to broaden their market presence.

Key Questions Addressed in the Report:

What is the Expected Value CAGR of the Shingles Vaccine Market from 2024 to 2031?
What are the Key Factors Driving the Growth of the Shingles Vaccine Market?
Which Region Holds the Largest Market Share in the Shingles Vaccine Market?
Who are the Key Players in the Global Shingles Vaccine Market?
What Strategies are Adopted by Leading Companies to Sustain Growth in the Shingles Vaccine Market?

Competitive Landscape and Business Strategies:

Leading companies in the shingles vaccine market include GlaxoSmithKline plc, Merck & Co., Inc., and Sanofi S.A. These companies focus on research and development, strategic partnerships, and market expansion to maintain their competitive edge.

Innovative vaccine formulations, such as adjuvanted and recombinant vaccines, are being developed to enhance vaccine efficacy and durability. Strategic collaborations with healthcare organizations and government agencies facilitate vaccine distribution and uptake, particularly in regions with high disease burden.

Key Companies Profiled:

GlaxoSmithKline plc
Merck & Co., Inc.
Sanofi S.A.
CSL Limited
Johnson & Johnson
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Emergent BioSolutions, Inc.
Novavax, Inc.
Valneva SE

Shingles Vaccine Market Segmentation:

By Product type:

Shingles
Zostavax
Sky Zoster

By Vaccine type:

Recombinant Vaccine
Live Attenuated Vaccine

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Product Code: PMRREP33198

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
3.3. Investment Feasibility Matrix
3.4. PESTLE and Porter's Analysis
3.5. Regulatory Landscape
- 3.5.1. By Key Regions
- 3.5.2. By Key Countries

4. Global Shingles Vaccine Market Analysis 2019-2023 and Forecast, 2024-2031

4.1. Historical Market Size Value (US$ Mn) Analysis, 2019-2023
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2024-2031
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis

5. Global Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Product Type

5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2019-2023
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
- 5.3.1. Shingrix
- 5.3.2. Zostavax
- 5.3.3. Sky Zoster
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2019-2023
5.5. Absolute $ Opportunity Analysis By Product Type, 2024-2031

6. Global Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Vaccination Type

6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Vaccination Type, 2019-2023
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Vaccination Type, 2024-2031
- 6.3.1. Recombinant Vaccine
- 6.3.2. Live Attenuated Vaccine
6.4. Y-o-Y Growth Trend Analysis By Vaccination Type, 2019-2023
6.5. Absolute $ Opportunity Analysis By Vaccination Type, 2024-2031

7. Global Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Region

7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2019-2023
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2024-2031
- 7.3.1. North America
- 7.3.2. Latin America
- 7.3.3. Europe
- 7.3.4. East Asia
- 7.3.5. South Asia
- 7.3.6. Oceania
- 7.3.7. MEA
7.4. Market Attractiveness Analysis By Region

8. North America Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 8.2.1. By Country
  - 8.2.1.1. U.S.
  - 8.2.1.2. Canada
- 8.2.2. By Product Type
- 8.2.3. By Vaccination Type
8.3. Market Attractiveness Analysis
- 8.3.1. By Country
- 8.3.2. By Product Type
- 8.3.3. By Vaccination Type
8.4. Key Takeaways

9. Latin America Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 9.2.1. By Country
  - 9.2.1.1. Brazil
  - 9.2.1.2. Mexico
  - 9.2.1.3. Argentina
  - 9.2.1.4. Rest of Latin America
- 9.2.2. By Product Type
- 9.2.3. By Vaccination Type
9.3. Market Attractiveness Analysis
- 9.3.1. By Country
- 9.3.2. By Product Type
- 9.3.3. By Vaccination Type
9.4. Key Takeaways

10. Europe Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 10.2.1. By Country
  - 10.2.1.1. Germany
  - 10.2.1.2. Italy
  - 10.2.1.3. France
  - 10.2.1.4. U.K.
  - 10.2.1.5. Spain
  - 10.2.1.6. Russia
  - 10.2.1.7. BENELUX
  - 10.2.1.8. Rest of Europe
- 10.2.2. By Product Type
- 10.2.3. By Vaccination Type
10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Product Type
- 10.3.3. By Vaccination Type
10.4. Key Takeaways

11. East Asia Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 11.2.1. By Country
  - 11.2.1.1. China
  - 11.2.1.2. Japan
  - 11.2.1.3. South Korea
- 11.2.2. By Product Type
- 11.2.3. By Vaccination Type
11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Product Type
- 11.3.3. By Vaccination Type
11.4. Key Takeaways

12. South Asia Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 12.2.1. By Country
  - 12.2.1.1. India
  - 12.2.1.2. Thailand
  - 12.2.1.3. Malaysia
  - 12.2.1.4. Indonesia
  - 12.2.1.5. Rest of South Asia
- 12.2.2. By Product Type
- 12.2.3. By Vaccination Type
12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Product Type
- 12.3.3. By Vaccination Type
12.4. Key Takeaways

13. Oceania Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 13.2.1. By Country
  - 13.2.1.1. Australia
  - 13.2.1.2. New Zealand
- 13.2.2. By Product Type
- 13.2.3. By Vaccination Type
13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Product Type
- 13.3.3. By Vaccination Type
13.4. Key Takeaways

14. MEA Shingles Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, By Country

14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 14.2.1. By Country
  - 14.2.1.1. GCC
  - 14.2.1.2. Rest of MEA
- 14.2.2. By Product Type
- 14.2.3. By Vaccination Type
14.3. Market Attractiveness Analysis
- 14.3.1. By Country
- 14.3.2. By Product Type
- 14.3.3. By Vaccination Type
14.4. Key Takeaways

15. Key Countries Shingles Vaccine Market Analysis

15.1. U.S.
- 15.1.1. Pricing Analysis
- 15.1.2. Market Share Analysis, 2024
  - 15.1.2.1. By Product Type
  - 15.1.2.2. By Vaccination Type
15.2. Canada
- 15.2.1. Pricing Analysis
- 15.2.2. Market Share Analysis, 2024
  - 15.2.2.1. By Product Type
  - 15.2.2.2. By Vaccination Type
15.3. Brazil
- 15.3.1. Pricing Analysis
- 15.3.2. Market Share Analysis, 2024
  - 15.3.2.1. By Product Type
  - 15.3.2.2. By Vaccination Type
15.4. Mexico
- 15.4.1. Pricing Analysis
- 15.4.2. Market Share Analysis, 2024
  - 15.4.2.1. By Product Type
  - 15.4.2.2. By Vaccination Type
15.5. Argentina
- 15.5.1. Pricing Analysis
- 15.5.2. Market Share Analysis, 2024
  - 15.5.2.1. By Product Type
  - 15.5.2.2. By Vaccination Type
15.6. Germany
- 15.6.1. Pricing Analysis
- 15.6.2. Market Share Analysis, 2024
  - 15.6.2.1. By Product Type
  - 15.6.2.2. By Vaccination Type
15.7. Italy
- 15.7.1. Pricing Analysis
- 15.7.2. Market Share Analysis, 2024
  - 15.7.2.1. By Product Type
  - 15.7.2.2. By Vaccination Type
15.8. France
- 15.8.1. Pricing Analysis
- 15.8.2. Market Share Analysis, 2024
  - 15.8.2.1. By Product Type
  - 15.8.2.2. By Vaccination Type
15.9. U.K.
- 15.9.1. Pricing Analysis
- 15.9.2. Market Share Analysis, 2024
  - 15.9.2.1. By Product Type
  - 15.9.2.2. By Vaccination Type
15.10. Spain
- 15.10.1. Pricing Analysis
- 15.10.2. Market Share Analysis, 2024
  - 15.10.2.1. By Product Type
  - 15.10.2.2. By Vaccination Type
15.11. Russia
- 15.11.1. Pricing Analysis
- 15.11.2. Market Share Analysis, 2024
  - 15.11.2.1. By Product Type
  - 15.11.2.2. By Vaccination Type
15.12. BENELUX
- 15.12.1. Pricing Analysis
- 15.12.2. Market Share Analysis, 2024
  - 15.12.2.1. By Product Type
  - 15.12.2.2. By Vaccination Type
15.13. China
- 15.13.1. Pricing Analysis
- 15.13.2. Market Share Analysis, 2024
  - 15.13.2.1. By Product Type
  - 15.13.2.2. By Vaccination Type
15.14. Japan
- 15.14.1. Pricing Analysis
- 15.14.2. Market Share Analysis, 2024
  - 15.14.2.1. By Product Type
  - 15.14.2.2. By Vaccination Type
15.15. South Korea
- 15.15.1. Pricing Analysis
- 15.15.2. Market Share Analysis, 2024
  - 15.15.2.1. By Product Type
  - 15.15.2.2. By Vaccination Type
15.16. India
- 15.16.1. Pricing Analysis
- 15.16.2. Market Share Analysis, 2024
  - 15.16.2.1. By Product Type
  - 15.16.2.2. By Vaccination Type
15.17. Thailand
- 15.17.1. Pricing Analysis
- 15.17.2. Market Share Analysis, 2024
  - 15.17.2.1. By Product Type
  - 15.17.2.2. By Vaccination Type
15.18. Malaysia
- 15.18.1. Pricing Analysis
- 15.18.2. Market Share Analysis, 2024
  - 15.18.2.1. By Product Type
  - 15.18.2.2. By Vaccination Type
15.19. Indonesia
- 15.19.1. Pricing Analysis
- 15.19.2. Market Share Analysis, 2024
  - 15.19.2.1. By Product Type
  - 15.19.2.2. By Vaccination Type
15.20. Australia
- 15.20.1. Pricing Analysis
- 15.20.2. Market Share Analysis, 2024
  - 15.20.2.1. By Product Type
  - 15.20.2.2. By Vaccination Type
15.21. New Zealand
- 15.21.1. Pricing Analysis
- 15.21.2. Market Share Analysis, 2024
  - 15.21.2.1. By Product Type
  - 15.21.2.2. By Vaccination Type
15.22. GCC Countries
- 15.22.1. Pricing Analysis
- 15.22.2. Market Share Analysis, 2024
  - 15.22.2.1. By Product Type
  - 15.22.2.2. By Vaccination Type

16. Market Structure Analysis

16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
- 16.3.1. By Regional
- 16.3.2. By Product Type
- 16.3.3. By Vaccination Type

17. Competition Analysis

17.1. Competition Deep Dive
- 17.1.1. GlaxoSmithKline plc.
  - 17.1.1.1. Overview
  - 17.1.1.2. Product Portfolio
  - 17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.1.4. Sales Footprint
  - 17.1.1.5. Strategy Overview
    - 17.1.1.5.1. Marketing Strategy
    - 17.1.1.5.2. Product Strategy
    - 17.1.1.5.3. Channel Strategy
- 17.1.2. Merck & Co., Inc.
  - 17.1.2.1. Overview
  - 17.1.2.2. Product Portfolio
  - 17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.2.4. Sales Footprint
  - 17.1.2.5. Strategy Overview
    - 17.1.2.5.1. Marketing Strategy
    - 17.1.2.5.2. Product Strategy
    - 17.1.2.5.3. Channel Strategy
- 17.1.3. SK Chemicals
  - 17.1.3.1. Overview
  - 17.1.3.2. Product Portfolio
  - 17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.3.4. Sales Footprint
  - 17.1.3.5. Strategy Overview
    - 17.1.3.5.1. Marketing Strategy
    - 17.1.3.5.2. Product Strategy
    - 17.1.3.5.3. Channel Strategy
- 17.1.4. Green Cross Corp
  - 17.1.4.1. Overview
  - 17.1.4.2. Product Portfolio
  - 17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.4.4. Sales Footprint
  - 17.1.4.5. Strategy Overview
    - 17.1.4.5.1. Marketing Strategy
    - 17.1.4.5.2. Product Strategy
    - 17.1.4.5.3. Channel Strategy
- 17.1.5. Geneone Life Science
  - 17.1.5.1. Overview
  - 17.1.5.2. Product Portfolio
  - 17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.5.4. Sales Footprint
  - 17.1.5.5. Strategy Overview
    - 17.1.5.5.1. Marketing Strategy
    - 17.1.5.5.2. Product Strategy
    - 17.1.5.5.3. Channel Strategy
- 17.1.6. Vaccitech
  - 17.1.6.1. Overview
  - 17.1.6.2. Product Portfolio
  - 17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.6.4. Sales Footprint
  - 17.1.6.5. Strategy Overview
    - 17.1.6.5.1. Marketing Strategy
    - 17.1.6.5.2. Product Strategy
    - 17.1.6.5.3. Channel Strategy
- 17.1.7. CanSinoBIO
  - 17.1.7.1. Overview
  - 17.1.7.2. Product Portfolio
  - 17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.7.4. Sales Footprint
  - 17.1.7.5. Strategy Overview
    - 17.1.7.5.1. Marketing Strategy
    - 17.1.7.5.2. Product Strategy
    - 17.1.7.5.3. Channel Strategy
- 17.1.8. Cipla Inc.
  - 17.1.8.1. Overview
  - 17.1.8.2. Product Portfolio
  - 17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.8.4. Sales Footprint
  - 17.1.8.5. Strategy Overview
    - 17.1.8.5.1. Marketing Strategy
    - 17.1.8.5.2. Product Strategy
    - 17.1.8.5.3. Channel Strategy
- 17.1.9. Pfizer Inc
  - 17.1.9.1. Overview
  - 17.1.9.2. Product Portfolio
  - 17.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
  - 17.1.9.4. Sales Footprint
  - 17.1.9.5. Strategy Overview
    - 17.1.9.5.1. Marketing Strategy
    - 17.1.9.5.2. Product Strategy
    - 17.1.9.5.3. Channel Strategy